Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...

BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

The “terror management theory” suggests that awareness of life’s finiteness shapes our actions and decisions. The third act is a chance to craft a love story that honors the past and evolves to meet ...

DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

The trial combines tislelizumab and Anktiva for treating advanced or metastatic non-small cell lung cancer patients. Credit: NMK-Studio/Shutterstock. ImmunityBio has entered a supply agreement and ...